To own Novartis, you need to believe in a diversified innovator that can offset patent and pricing headwinds with new drugs in renal, oncology and immunology. The Vanrafia IgAN data supports that pipeline story but does not materially change the near term focus on 2026 guidance, where management already expects low single digit sales growth and a low single digit decline in core operating income. Key risk remains execution across late stage programs and pricing pressure in major markets.<\/p>\n
Among recent announcements, the proposed CHF 3.70 per share dividend for 2025 stands out in this context. It signals confidence in cash generation even as Novartis absorbs impairment charges and plans only modest growth for 2026. For investors watching Vanrafia and the broader autoimmune and renal push, that dividend track record can matter as a counterweight to clinical, reimbursement and competition risks while waiting for pipeline catalysts to play out.<\/p>\n
Yet against this steady dividend story, investors should still pay attention to the risk that pricing pressure and late stage pipeline setbacks could…<\/p>\n
Read the full narrative on Novartis (it’s free!)<\/a><\/p>\n Novartis’ narrative projects $59.1 billion revenue and $17.3 billion earnings by 2028. This requires 2.3% yearly revenue growth and a $3.6 billion earnings increase from $13.7 billion.<\/p>\n Uncover how Novartis’ forecasts yield a CHF113.58 fair value<\/a>, a 9% downside to its current price.<\/p>\n Some of the lowest ranked analysts were assuming roughly flat revenue near US$56.9 billion and only US$14.2 billion of earnings by 2028, so compared with the baseline narrative around Vanrafia and the renal pipeline they paint a much more cautious picture that you should weigh against this new data.<\/p>\n Explore 4 other fair value estimates on Novartis<\/a> – why the stock might be worth over 2x more than the current price!<\/p>\n Disagree with existing narratives? Create your own in under 3 minutes<\/a> – extraordinary investment returns rarely come from following the herd.<\/p>\n Our top stock finds are flying under the radar-for now. Get in early:<\/p>\n This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n Companies discussed in this article include NOVN.SW<\/a>.<\/p>\n Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"In early February 2026, Novartis reported final Phase III ALIGN data showing its IgA nephropathy drug Vanrafia (atrasentan)…\n","protected":false},"author":2,"featured_media":134,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[10486,6646,206],"class_list":{"0":"post-14526","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-autoimmune-diseases","9":"tag-kidney-function","10":"tag-novartis"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/14526","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=14526"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/14526\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/134"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=14526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=14526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=14526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"SWX:NOVN](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/02\/3b9bcca0c95746ce49bb1e1a63540a7f.png\")
<\/a> SWX:NOVN 1-Year Stock Price Chart <\/p>\n